Twenty state attorneys general sued a group of generic drug companies Thursday, accusing them of conspiring to fix prices on an antibiotic and a diabetes medication.
The suit comes a day after price-fixing charges against former executives at one of the drugmakers were unsealed in a Justice Department antitrust probe.
The attorneys general, including New York’s Eric Schneiderman and Connecticut’s George Jepsen, alleged in a suit filed in Connecticut federal court that Heritage Pharmaceuticals; Aurobindo Pharma USA; Citron Pharma; Mayne Pharma; Mylan Pharmaceuticals; and Teva Pharmaceuticals USA, conspired to manipulate prices for doxycycline hyclate, an antibiotic, and glyburide, used in the treatment of diabetes.
On Wednesday, federal prosecutors unsealed charges against Heritage’s former chief executive and former president, alleging they conspired with competitors to fix prices and allocate customers for the same two drugs.
Heritage has said it fired those executives and is cooperating with the Justice Department.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UFC Reaches $375 Million Settlement in Antitrust Case
Feb 6, 2025 by
CPI
Brazilian Architecture Council Convicted of Antitrust Violations
Feb 6, 2025 by
CPI
Bipartisan Bill Seeks to Ban Chinese AI Software from US Government Devices
Feb 6, 2025 by
CPI
Senators Call for Investigation into RealPage Algorithm’s Impact on Military Housing Costs
Feb 6, 2025 by
CPI
ECB Seeks Faster Digital Euro Legislation Amid US Stablecoin Push
Feb 6, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon